Standout Papers

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safe... 2010 2026 2015 2020 2.3k
  1. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2010)
    Julie R. Brahmer, Charles G. Drake et al. Journal of Clinical Oncology

Immediate Impact

26 by Nobel laureates 17 from Science/Nature 149 standout
Sub-graph 1 of 17

Citing Papers

Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot
2022 Standout
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
2022 Standout

Works of Alice Pons being referenced

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
2010 Standout

Author Peers

Author Last Decade Papers Cites
Alice Pons 2381 1294 406 656 8 2.8k
Theresa M. Salay 2079 1329 480 570 6 2.6k
Michael Binder 2068 951 431 802 14 2.8k
Oliver Bohnsack 1993 941 384 693 11 2.4k
Jake S. O’Donnell 2020 1390 863 643 17 3.0k
Colm R. Duffy 1598 1118 504 379 11 2.2k
Hanane Ouakrim 1451 1199 363 555 16 2.1k
Jonathan J. Havel 1844 1054 804 666 14 2.6k
Ira Wollner 2580 1341 481 727 31 3.3k
Michael A. Postow 2927 1692 715 669 18 3.9k
Geoffrey D. Young 2252 1374 725 501 28 3.1k

All Works

Loading papers...

Rankless by CCL
2026